AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Shares of AbbVie Inc. ABBV rose 1.79% to $200.88 Thursday, on what proved to be an all-around poor trading session for the ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.

Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...

Currently, shares trade at $170.30, meaning your investment's value could have grown to $26,989 from stock price appreciation alone. However, AbbVie also paid dividends during these 10 years.

With the shares kicking off 2025 with a solid 8% gain year to date, some investors may wonder -- can the rally keep going, and is AbbVie stock a buy right now? Here's what you need to know.